Li Zhang
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Anti-LAG-3 Antibody LBL-007 plus Tislelizumab and Chemotherapy as First-Line Therapy for Advanced Nasopharyngeal Carcinoma: A Multicenter Phase 2 Trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: June 04, 2025
Anti-OX40 antibody BAT6026 in patients with advanced solid tumors: A multi-center phase I study.
Journal: iScience
Published: August 01, 2024
HDL-cholesterol confers sensitivity of immunotherapy in nasopharyngeal carcinoma via remodeling tumor-associated macrophages towards the M1 phenotype.
Journal: Journal for immunotherapy of cancer
Published: May 27, 2024
Case report: Leptomeningeal metastasis of advanced nasopharyngeal carcinoma treated with chemoimmunotherapy.
Journal: Human vaccines & immunotherapeutics
Published: December 19, 2023
Genomic and microbial factors affect the prognosis of anti-pd-1 immunotherapy in nasopharyngeal carcinoma.
Journal: Frontiers in oncology
Published: May 26, 2022
Targeting cancer cell plasticity by HDAC inhibition to reverse EBV-induced dedifferentiation in nasopharyngeal carcinoma.
Journal: Signal transduction and targeted therapy
Published: February 08, 2021
Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes.
Journal: Molecular cancer research : MCR
Published: March 13, 2017
ABO blood group, Epstein-Barr virus infection and prognosis of patients with non-metastatic nasopharyngeal carcinoma.
Journal: Asian Pacific journal of cancer prevention : APJCP
Published: September 18, 2014
Showing 1-9 of 9
Last Updated: 09/26/2026